Critics accuse ADA of shifting towards costly drug treatments at the expense of prevention and equity

The American Diabetes Association faces renewed scrutiny over its clinical guidelines, with critics warning that its emphasis on expensive drug therapies like Ozempic and Wegovy risks widening health disparities and sidelining preventive care strategies.

The American Diabetes Association is under fresh scrutiny after a recent critique in STAT News argued that its latest clinical guidance marks a broader shift towards costly drug-based treatment, rather than the more accessible, preventive approach long associated with diabetes advocacy. The debate comes as GLP-1 medicines such as Ozempic and Wegovy have moved to the centre of diabetes and weight-loss care, even as questions mount over who can actually obtain them.

The criticism focuses on how the association’s standards have evolved in ways that appear to lower the bar for starting intensive drug therapy while giving less prominence to the social and environmental drivers of type 2 diabetes. The STAT News authors, Prashant Yadav, Thomas J. Bollyky, Rush Doshi, Paul Friedrichs and Victor Suarez, argue that this reflects a departure from the ADA’s earlier willingness to challenge unhealthy commercial influences and push for broader lifestyle-based solutions.

Access remains a central concern. A study cited by Axios in August 2024 found prescriptions for Ozempic and Wegovy surged by 442% between January 2021 and December 2023, yet patients on Medicare and Medicaid were less likely to receive them than those with private cover. KFF has separately reported that Affordable Care Act marketplace plans rarely cover GLP-1 medicines used solely for obesity, while diabetes indications are covered far more often, though usually with prior authorisation or other controls.

The pricing picture has improved only slightly. GoodRx says these drugs can cost more than $1,000 a month without insurance, even if discounts or savings schemes can reduce the bill. Novo Nordisk has since said it will lower the cash price of Wegovy and Ozempic, while also cutting the Medicare price for GLP-1 treatments used in diabetes to $245 a month, but analysts and advocates say the medicines still remain out of reach for many patients and the coverage gap remains substantial.